Resverlogix Corp. (Resverlogix) is a Canada-based clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The Company is engaged in developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis, which is in phase 2b clinical trials. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds from the Company�s epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including cancer, autoimmune and neurodegenerative disorders. As of August 31, 2012, the Company had completed SUSTAIN and ASSURE clinical trials,seven clinical trials, with participation by approximately 950 subjects. In June 2013, Resverlogix Corp spun-out RVX Therapeutics Inc. to Zenith Epigenetics Corp.